Milk Thistle Extract for Chemotherapy-Induced Liver Toxicity
Name of the Trial
Why Is This Trial Important?
Although necessary, many chemotherapy drugs used to treat ALL cause harmful side effects, including liver damage. Consequently, treatment doses must often be reduced or withheld.
In this trial, researchers are testing the ability of a nutritional supplement called silymarin to treat liver damage caused by chemotherapy for ALL. Silymarin is an extract of the milk thistle plant and has been shown in laboratory and animal studies to protect the liver from certain toxic chemicals.
"We observed that some parents of children undergoing treatment for ALL were using milk thistle supplements to lessen the effects of liver toxicity, in some cases with noticeable improvement," said Dr. Kelly. "With this trial, we are trying to verify milk thistle's efficacy in reducing chemotherapy-related liver toxicity.
"Additionally, we are exploring the interaction between milk thistle supplements and the chemotherapy drugs used to treat ALL, and so far we have found no evidence of an adverse interaction."
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.